Agios Pharmaceuticals's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Agios Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
AGIO's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.7 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Agios Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
AGIO vs ABCL, KOD, IMNM: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Agios Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Agios Pharmaceuticals (AGIO) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Agios Pharmaceuticals and its competitors. According to the industry distribution chart, Agios Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry.
Is Agios Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Agios Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Agios Pharmaceuticals ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' 5-Year Yield-on-Cost % compare to ABCL and KOD?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Agios Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.70, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (AGIO) is currently considered Possible Value Trap. The stock's GF Value™ is $84.69, compared to a current price of $41.23 — trading 51.3% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Agios Pharmaceuticals (AGIO), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (AGIO) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 51.3% below its estimated GF Value™ of $84.69.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for AGIO:
5-Year Yield-on-Cost %: 0.00
GF Value™: $84.69 vs. price of $41.23 (51.3% below fair value)
No single metric tells the full story. See the AGIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for AGIO
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGIO has been successfully added to your 